How I treat heparin-induced thrombocytopenia and thrombosis

Blood

Volumn 101, Issue 1, 2003, Pages 31-37

  Alving, Barbara M ^a  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARGATROBAN; DANAPAROID; FONDAPARINUX; HEPARIN; HIRULOG; LEPIRUDIN; WARFARIN;

ANTIBODY PRODUCTION; CLINICAL FEATURE; CLINICAL TRIAL; CORONARY ARTERY BYPASS GRAFT; DIALYSIS; DRUG CHOICE; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG SAFETY; DRUG WITHDRAWAL; ENZYME LINKED IMMUNOSORBENT ASSAY; HIGH RISK POPULATION; HUMAN; INTENSIVE CARE; INTERNATIONAL STANDARD UNIT; MEDICAL DECISION MAKING; PARTIAL THROMBOPLASTIN TIME; PATIENT COUNSELING; PREGNANCY; PRIORITY JOURNAL; PROSPECTIVE STUDY; REVIEW; RISK ASSESSMENT; THROMBOCYTOPENIA; THROMBOSIS;

EID: 0037220153     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2002-04-1089     Document Type: Review

References (43)

1. Kelton JG. The clinical management of heparin-induced thrombocytopenia. Semin Hematol. 1999;36:17-21.
2. Walenga, JM, Jeske, WP, Wood JJ, Atiman S, Lewis BE, Bakhos M. Laboratory tests for heparin-induced thrombocytopenia: A multicenter study. Semin Hematol. 1999;36:22-28.
3. Warkentin TE, Kelton JG. Temporal aspects of heparin-induced thrombocytopenia. N Engl J Med. 2001;344:1286-1292.
4. Warkentin TE, Sheppard JI, Horsewood P, et al. Impact of the patient population on the risk for heparin-induced thrombocytopenia. Blood. 2000;96:1703-1708.
5. Visentin GP, Malik M, Cyganiak KA, Aster RH. Patients treated with unfractionated heparin during open heart surgery are at high risk to form antibodies reactive with heparin: Platelet factor 4 complexes. J Lab Clin Med. 1996;128:376-382.
6. Bauer TL, Gowthami A, Konkle BA, et al. Prevalence of heparin-associated antibodies without thrombosis in patients undergoing cardiopulmonary bypass surgery. Circulation. 1997;95:1242-1246.
7. Jackson MR, Gillespie DL, Chang AS, et al. The incidence of heparin-induced antibodies in patients undergoing vascular surgery: A prospective study. J Vasc Surg. 1998;28:439-445.
8. Warkentin TE, Kelton JG. Delayed onset heparin-induced thrombocytopenia and thrombosis. Ann Intern Med. 2001;135:502-506.
9. Greinacher, A, Eichler P, Lubenow N, Kwasny H, Luz M. Heparin-induced thrombocytopenia with thromboembolic complications: Meta-analysis of 2 prospective trials to assess the value of parenteral treatment with lepirudin and its therapeutic aPTT range. Blood. 2000;96:846-851.
10. Vanholder R, Camez A, Veys N, Van Loo A, Dhondt AM, Ringoir S, Pharmacokinetics of recombinant hirudin in hemodialyzed end-stage renal failure patients. Thromb Haemost. 1997;77:650-655.
11. Huhle G, Hoffmann U, Song X, Wang LC, Heene DL, Harenberg J. Immunologic response to recombinant hirudin in HIT type II patients during long-term treatment. Br J Haematol. 1999;106:195-201.
12. Eichler P, Friesen HJ, Lubenow N, Jaeger B, Greinacher A. Antihirudin antibodies in patients with heparin-induced thrombocytopenia treated with lepirudin: Incidence, effects on aPTT, and clinical relevance. Blood. 2000;96:2373-2378.
13. Lewis BE, Wallis DE, Berkowitz SD, et al. Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia. Circulation. 2001;103:1838-1843.
14. Hijikata-Okunomiya A, Okamoto S. A strategy for a rational approach to designing synthetic selective inhibitors. Semin Thromb Hemost. 1992;18:135-149.
15. Swan SK, Hursting MJ. The pharmacokinetics and pharmacodynamics of argatroban: Effects of age, gender, and hepatic or renal dysfunction. Pharmacotherapy. 2000;20:318-329.
16. Hursting MJ, Zehnder JL, Joffrion JL, Becker JC, Knappenberger GD, Schwarz RP Jr. The international normalized ratio during concurrent warfarin and argatroban anticoagulation: Differential contributions of each agent and effects of the choice of thromboplastin used. Clin Chem. 1999;45:409-412.
17. Reid TJ III, Alving BM. A quantitative thrombin time for determining levels of hirudin and Hirulog. Thromb Haemost. 1993;70:608-616.
18. Pötzsch B, Madlener K, Seeling C, et al. Monitoring of r-hirudin anticoagulation during cardiopulmonary bypass - Assessment of the whole blood Ecarin clotting time. Thromb Haemost. 1997;77:920-925.
19. Koster A, Loebe M, Hansen R, et al. A quick assay for monitoring recombinant hirudin during cardiopulmonary bypass in patients with heparin-induced thrombocytopenia type II: Adaption of the Ecarin clotting time to the act II device. J Thorac Cardiovasc Surg. 2000;119:1278-1283.
20. Danhof M, deBoer A, Magnani HN, Stiekema JC. Pharmacokinetic considerations on Orgaran (Org 10172) therapy. Hemostasis. 1992;22:73-84.
21. de Valk HW, Banga JD, Wester JWJ, et al. Comparing subcutaneous danaparoid with intravenous unfractionated heparin for the treatment of venous thromboembolism (a randomized controlled trial). Ann Intern Med. 1995;123:1-9.
22. Laposata M, Green D, Van Cott EM, Barrowcliffe TW, Goodnight SH, Sosolik RC. College of American Pathologists Conference XXXI on laboratory monitoring of anticoagulant therapy. The clinical use and laboratory monitoring of low-molecular weight heparin, danaparoid, hirudin, and related compounds, and argatroban. Arch Pathol Lab Med. 1998;122:799-807.
23. Tardy-Poncet B, Tardy B, Reynaud J, et al. Efficacy and safety of danaparoid sodium (ORG 10172) in critically ill patients with heparin-associated thrombocytopenia. Chest. 1999;115:1616-1620.
24. Matsuo T, Kario K, Chikahira Y, Nakao K, Yamada T. Treatment of heparin-induced thrombocytopenia by use of argatroban, a synthetic thrombin inhibitor. Br J Haematol. 1992;82:627-629.
25. Vanholder RC, Camez AA, Veys NM, et al. Recombinant hirudin: A specific thrombin inhibiting anticoagulant for hemodialysis. Kidney Int. 1994;45:1754-1759.
26. Fischer K-G, van de Loo A, Bohler J. Recombinant hirudin (lepirudin) as anticoagulant in intensive care patients treated with continuous hemodialysis. Kid Internat. 1999;56:S46-S50.
27. Chong BH, Magriani HN. Orgaran in heparin-induced thrombocytopenia. Hemostasis. 1992;22:85-91.
28. Lathan P, Revelis A, Joshi GP, DiMaio JM, Jessen ME. Use of recombinant hirudin in patients with heparin-induced thrombocytopenia with thrombosis requiring cardiopulmonary bypass. Anesthesiology. 2000;92:263-266.
29. Jackson MR, Danby CA, Alving BM. Heparinoid anticoagulation and topical fibrin sealant in heparin-induced thrombocytopenia. Ann Thorac Surg. 1997;64:1815-1817.
30. Potzsch B, Riess FC, Volpel H, Muller-Berghaus G, Greinacher. Recombinant hirudin as anticoagulant during open-heart surgery. Thromb Haemost. 1995;73:1456a.
31. Koster a, Kuppe H, Hetzer R, et al. Emergent cardiopulmonary bypass in five patients with heparin-induced thrombocytopenia type II employing recombinant hirudin. Anesthesiology. 1998;89:777-780.
32. Longrois D, de Maistre E, Bischoff N, Dopff C, et al. Recombinant hirudin anticoagulation for aortic valve replacement in heparin-induced thrombocytopenia. Can J Anesth. 2000;47:255-260.
33. Parent F, Bridey F, Dreyfus M, et al. Treatment of severe venous thrombo-embolism with intravenous hirudin (HBW 023): An open pilot study. Thromb Haemost. 1993;3:386-388.
34. Lewis BE, Iaffaldano R, McKiernan TL, et al. Report of successful use of argatroban as an alternative anticoagulant during coronary stent implantation in a patient with heparin-induced thrombocytopenia and thrombosis syndrome. Catheter Cardiovasc Diag. 1996;38:206-209.
35. Matthai WH Jr. Use of argatroban during percutaneous coronary interventions in patients with heparin-induced thrombocytopenia. Semin Thromb Hemost. 1999;25:57-60.
36. Lewis BE, Matthai WH Jr, Cohen M, et al. Argatroban anticoagulation during percutaneous coronary intervention in patients with heparin-induced thrombocytopenia. Catheter Cardiovasc Intervent. 2002;57:177-184.
37. Bittl JA, Strony J, Brinker JA, et al. Treatment with bivalirudin (Hirulog) as compared with heparin during coronary angioplasty for unstable or postinfarction angina. N Engl J Med. 1995;333:764-769.
38. Manfredi JA, Wall RP, Sane DC, Braden GA. Lepirudin as a safe alternative for effective anticoagulation in patients with known heparin-induced thrombocytopenia undergoing percutaneous coronary intervention: Case reports. Catheter Cardiovasc Intervent. 2001;52:468-472.
39. Tardy B, Tardy-Poncet B, Fournel P, et al. Lower limb veins should be systematically explored in patients with isolated heparin-induced thrombocytopenia. Thromb Haemost. 1999;82:1199-1200.
40. Warkentin T, Kelton JG. A 14-year study of heparin-induced thrombocytopenia. Am J Med. 1996;101:502-507.
41. Warkentin TE, Elavathil LJ, Hayward CPM, et al. The pathogenesis of venous limb gangrene associated with heparin-induced thrombocytopenia. Ann Intern Med. 1997;127:804-812.
42. Hirsh J, Warkentin TE, Shaughnessy SG, et al. Heparin and low-molecular weight heparin. Mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest. 2001;119:80S-94S.
43. Farner B, Eichler P, Kroll H, Greinacher A. A comparison of danaparoid and lepirudin in heparin-induced thrombocytopenia. Thromb Haemost. 2001;85:950-957.